With $460B in bor­row­ing ca­pac­i­ty, will any of the Big-20 bio­phar­mas go af­ter one of the top-5 takeover tar­gets?

Leerink’s al­ways in­ter­est­ing Ge­of­frey Porges knows how to get your at­ten­tion. And noth­ing turns the head faster than a list of ma­jor league take­out tar­gets.

Now that Take­da has lined up its $62 bil­lion deal to buy Shire $SH­PG, with­out work­ing too hard to line up the mon­ey, Porges de­cid­ed to bring out the cal­cu­la­tor to see what in­dus­try lead­ers could do if they re­al­ly want­ed to buy Some­thing Big. And then al­so added a few key tar­gets that would get the bankers to stomp the ground in an­tic­i­pa­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER